Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Reversal of an Unfavorable Effect of Hydrochlorothiazide Compared to Angiotensin Converting Enzyme Inhibitor on Serum Uric Acid and Oxypurines Levels by Estrogen-progestin Therapy in Hypertensive Postmenopausal Women.

NCT03921736 is registered in ClinicalTrials.gov with Anna Posadzy-Małaczyńska as lead sponsor.

NCT NCT03921736
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03921736 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Reversal of an Unfavorable Effect of Hydrochlorothiazide Compared to Angiotensin Converting Enzyme Inhibitor on Serum Uric Acid and Oxypurines Levels by Estrogen-progestin Therapy in Hypertensive Postmenopausal Women.
Lead sponsor
Anna Posadzy-Małaczyńska
Phase
Phase 4
Overall status
Completed
Start date
January 10, 2000
Completion date
November 17, 2005
Enrollment
180 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension, hyperuricemia, menopause